NOTES PAYABLE AND CONVERTIBLE PROMISSORY NOTES (Tables)

9 Months Ended

Sep. 30, 2023

The following table summarizes the Company’s outstanding term loans:

SCHEDULE OF OUTSTANDING TERM LOANS

	September 30, 2023			December 31, 2022
2019 Term Loan	$	5,676,900		$	5,676,900
2022 Term Loans		3,045,634			2,365,079
2023 Term Loans		1,332,143			-
Notes payable		10,054,677			8,041,979
Unamortized discounts and fees		(394,322	)		(709,001	)
Loans payable	$	9,660,355		$	7,332,978

SCHEDULE OF CONVERTIBLE PROMISSORY NOTES

The following table summarizes the Company’s outstanding convertible notes as of September 30, 2023, and December 31, 2022:

	September 30, 2023		December 31, 2022
Convertible Notes	$	1,168,765	$	1,319,024
Unamortized discounts		-		(67,328	)
Convertible notes payable, net	$	1,168,765	$	1,251,696

SCHEDULE OF FAIR VALUE OF DERIVATIVE LIABILITIES ESTIMATED ISSUANCE AND VALUATION MODE

During the nine months ended September 30, 2023, the fair value of the derivative liabilities was estimated at issuance and at the September 30, 2023, using the Binomial Lattice valuation model with the following assumptions:

Dividend rate	—	%
Term (in years)	0.00 to 1.10 year
Volatility	178.2% to 409	%
Risk-free interest rate	3.36% to 5.55	%

Adhera Therapeutics, Inc. 10-Q